Need professional-grade analysis? Visit stockanalysis.com
$67.46M
7.55
301
N/A
hVIVO plc (HVO) trades on London Stock Exchange in GBX. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at GBX7.60, down 16.94% from the previous close.
Over the past year, HVO has traded between a low of GBX4.59 and a high of GBX18.88. The stock has lost 56.1% over this period. It is currently 59.8% below its 52-week high.
hVIVO plc has a market capitalization of $67.46M, with a price-to-earnings ratio of 7.55.
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and COPD. In addition, the company offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, it provides preclinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company offers services to big pharma and biotech organizations. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
Side-by-side comparison against top Healthcare peers.